Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 11/20 | 0.48 |
| ▸ | PTAFR | P25105 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18110395 | 1.00 | TBXAS1 (0.48) | TBXAS1PTAFRKDM4ELMNACHRNA7 | |
| SCHEMBL18110393 | 0.85 | MAPK1 (0.38) | LMNA | |
| SCHEMBL18110415 | 0.80 | LMNA (0.35) | KDM4ELMNA | |
| SCHEMBL18112891 | 0.79 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL18110380 | 0.79 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL18110355 | 0.79 | CYP1A2 (0.42) | — | |
| SCHEMBL10398649 | 0.78 | TBXAS1 (0.59) | TBXAS1PTAFRKDM4ELMNATDP1 | |
| SCHEMBL10398650 | 0.78 | TBXAS1 (0.59) | TBXAS1PTAFRKDM4ELMNATDP1 | |
| SCHEMBL18110391 | 0.78 | ADAMTS4 (0.41) | — | |
| SCHEMBL18110390 | 0.77 | MMP13 (0.42) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | ALLERGAN, INC. (US) | 2018-09-18 | — | — | US | disclosed |
| EP-3277704-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016160362-A1 | CYCLOSPORINS MODIFIED ON THE MEBMT SIDECHAIN BY HETEROCYCLIC RINGS | ALLERGAN, INC. (US) | 2016-10-06 | — | — | WO | disclosed |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | ALLERGAN, INC. | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10077289-B2 | Cyclosporins modified on the MeBmt sidechain by heterocyclic rings | CHP1, UACA, CRYAB | TBXAS1 1038/4885PTAFR 3532/4885KDM4E 2474/4885 |
| US-20160289271-A1 | Cyclosporins Modified on the MeBmt Sidechain by Heterocyclic Rings | CHP1, UACA, CRYAB | TBXAS1 1038/4885PTAFR 3532/4885KDM4E 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.